{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=57",
    "query": {
      "intervention": "Formulation #1",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 1760,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=58&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=56&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T20:54:08.411Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02435212",
      "title": "Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transfusion-dependent Anemia"
      ],
      "interventions": [
        {
          "name": "Deferasirox granule formulation",
          "type": "DRUG"
        },
        {
          "name": "Deferasirox DT formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 224,
      "start_date": "2015-10-21",
      "completion_date": "2024-01-15",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-08T20:54:08.411Z",
      "location_count": 13,
      "location_summary": "Oakland, California • Atlanta, Georgia • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02435212"
    },
    {
      "nct_id": "NCT03486834",
      "title": "V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus (CMV) Infections"
      ],
      "interventions": [
        {
          "name": "V160",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 35 Years · Female only"
      },
      "enrollment_count": 2200,
      "start_date": "2018-04-30",
      "completion_date": "2021-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-01-23",
      "last_synced_at": "2026-11-08T20:54:08.411Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Rialto, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03486834"
    },
    {
      "nct_id": "NCT05089019",
      "title": "A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Loxo Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 224,
      "start_date": "2021-10-29",
      "completion_date": "2022-07-19",
      "has_results": true,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-11-08T20:54:08.411Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05089019"
    },
    {
      "nct_id": "NCT07813130",
      "title": "A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "AB126 Neural Exosomes Intravenous Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AB126 Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Aruna Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-10",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-11-08T20:54:08.411Z",
      "location_count": 3,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07813130"
    },
    {
      "nct_id": "NCT00821444",
      "title": "Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ziprasidone",
          "type": "DRUG"
        },
        {
          "name": "B16 Fasted",
          "type": "DRUG"
        },
        {
          "name": "B16 Fed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 11,
      "start_date": "2009-01",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-11-08T20:54:08.411Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821444"
    },
    {
      "nct_id": "NCT00821964",
      "title": "Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Male Breast Cancer",
        "Recurrent Breast Cancer",
        "Skin Metastases",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "imiquimod",
          "type": "DRUG"
        },
        {
          "name": "Abraxane",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "RNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2008-12",
      "completion_date": "2012-11-29",
      "has_results": true,
      "last_update_posted_date": "2018-01-02",
      "last_synced_at": "2026-11-08T20:54:08.411Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821964"
    },
    {
      "nct_id": "NCT02197416",
      "title": "Safety of Dabigatran Etexilate in Blood Clot Prevention in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Secondary Prevention"
      ],
      "interventions": [
        {
          "name": "dabigatran etexilate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 214,
      "start_date": "2014-09-29",
      "completion_date": "2019-11-19",
      "has_results": true,
      "last_update_posted_date": "2020-06-04",
      "last_synced_at": "2026-11-08T20:54:08.411Z",
      "location_count": 9,
      "location_summary": "Sacramento, California • Miami, Florida • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197416"
    },
    {
      "nct_id": "NCT05031806",
      "title": "Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "iNexin™ (0.08% aCT1)",
          "type": "DRUG"
        },
        {
          "name": "iNexin™ (0.4% aCT1)",
          "type": "DRUG"
        },
        {
          "name": "iNexin™ (2.0% aCT1)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (eye drop formulation without aCT1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xequel Bio, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-09-28",
      "completion_date": "2021-12-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-04",
      "last_synced_at": "2026-11-08T20:54:08.411Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05031806"
    },
    {
      "nct_id": "NCT06720714",
      "title": "A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Rozanolixizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2024-12-03",
      "completion_date": "2025-05-12",
      "has_results": true,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-11-08T20:54:08.411Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06720714"
    },
    {
      "nct_id": "NCT02509104",
      "title": "Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Hyperplasia"
      ],
      "interventions": [
        {
          "name": "FDC capsule of dutasteride and tamsulosin",
          "type": "DRUG"
        },
        {
          "name": "Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 56,
      "start_date": "2015-07-30",
      "completion_date": "2015-10-10",
      "has_results": false,
      "last_update_posted_date": "2018-06-19",
      "last_synced_at": "2026-11-08T20:54:08.411Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02509104"
    }
  ]
}